Kurma Partners Makes €140M First Close on €250M VC Biotech Fund

Paris-based Kurma Partners announced a €140M first close on its fourth VC biotech fund, targeting a total fundraise of €250M by its final close in 2025.

In an October 3 news release, Kurma said its Biofund IV is seeking to make 16-20 new investments following a similar strategy to its three predecessor funds, which are “dedicated to companies developing innovative therapeutics, aiming for a balanced, risk-managed strategy, with investments for company creation as well as in established venture-stage companies.”

Kurma said the new fund has already made three investments, one in autoimmune company SciRhom, another in cancer immunotherapy company Avidicure, and the third in Memo Therapeutics.

View the press release here.

Written By: Matt Hirst, Editorial Director

Related Content

Maine PERS Mulls Add’l $150M+ to TPG Angelo Gordon’s Twin Brook
February 11, 2025

San Jose Police & Fire Commits $158M to Alts in December 2024 Deals
February 11, 2025

Emigrant Stakes $2.8B CT HNW Advisor Principle Wealth
February 11, 2025

Cresset Rebrands Private Funds Business as Peakline Partners
February 11, 2025

Report: BC Partners Targets €6B Raise for 12th Flagship Fund
February 11, 2025

The Database For Cold Outreach to Reach Institutional and RIA Investors

Book A Demo

Kurma Partners Makes €140M First Close on €250M VC Biotech Fund

Subscribe

Related Content

The Database For Cold Outreach to Reach Institutional and RIA Investors

Address

Products & Services

Resources

Events

Company